News
Ivy Fertility acquires California-based practice
California remains one of the states with the largest number of fertility clinics

Ivy Fertility has acquired the Mountain View fertility practice NOVA IVF to expand reproductive health services across California.
NOVA IVF, a California-based fertility and IVF clinic led by Dr Richard Schmidt and Dr Meera Shah, provides services including treatment for unexplained infertility, male infertility, tubal infertility, endometriosis infertility, and implantation issues.
In addition to IVF treatments, it also offers egg donation and egg freezing services, oocyte donation combined with gestational surrogacy, and preimplantation genetic testing.
By partnering with Ivy Fertility, the Mountain View practice aims to expand its offerings and help more people conceive.
“Many in our community have invested extraordinary time for their studies and careers, creating a greater need for fertility services in later reproductive years,” said Dr Richard Schmidt.
“Ivy Fertility is the perfect partner for the future of our practice. This collaboration will allow us to expand our capabilities and serve even more people who want to become parents.”
Lisa Van Dolah, CEO of Ivy Fertility, said: “Drs Schmidt and Shah are deeply respected physicians in the Bay and among reproductive endocrinologists worldwide. We’re thrilled they chose Ivy as their partner.
“With the addition of NOVA IVF, Ivy Fertility centres now represent more IVF cycles in California than any other fertility network.
“I’m proud of the responsibility and privilege to serve over 6,600 families per year in California. The Ivy Fertility network now includes 40 reproductive endocrinologists in 23 locations across eight states.”
While first-rate fertility clinics can be found throughout the US, California has been described as “a hotbed” for advancements in the field both for American families and for an ever-growing wave of families from abroad.
According to CDC, a total of 489 fertility clinics in the US performed assisted reproductive technology procedures in 2019. California was the state with the largest numbers of fertility clinics, followed by New York and Texas.
Insight
Common cancer marker may play active role in preventing the disease, study finds

Ki-67, a protein used to measure tumour growth, may also help prevent chromosome errors that drive cancer, a study suggests.
The findings could change how scientists view Ki-67, a marker commonly used in breast cancer and other tumours to assess how quickly cancer cells are growing.
Researchers found the protein may help preserve genome stability by maintaining the structural integrity of centromeres, key parts of chromosomes that help ensure DNA is shared correctly during cell division.
The research was led by professor Paola Vagnarelli at Brunel University of London in collaboration with scientists at the University of Edinburgh and the Technical University of Berlin.
Professor Vagnarelli said: “Doctors already measure Ki-67 to see how aggressive a cancer might be. But our results suggest it is actually helping maintain genome stability.
“That means it may be more than a marker. It could potentially also be a therapeutic target.”
The study examined three proteins that attach to chromosomes during cell division and help rebuild the molecular system that tells each new cell what kind of cell it is.
Every human cell carries identical DNA. What makes a liver cell different from a brain cell is which genes are switched on and which are kept inactive.
When a cell divides, that entire system of switches must be rebuilt. The three proteins involved in this process were Ki-67, Repo-Man and PNUTS.
Vagnarelli’s team developed a method that individually removes each protein from a living cell at the precise point of division. Older techniques could not isolate that moment cleanly.
They found that cells rely on all three proteins to reset themselves after division, but each failed in a different way when removed.
Without PNUTS, gene activity spiralled out of control and thousands of genes switched on at once.
Without Repo-Man, cells escaped safety checkpoints that usually stop damaged or abnormal cells from continuing to divide.
“What we didn’t expect was how clean the separation was,” said Vagnarelli.
Each protein fails in its own specific way. There is no redundancy, no safety net. Which means there are three separate points at which this process can go wrong.
“When the system breaks down, cells can emerge with the wrong number of chromosomes. That condition, called aneuploidy, is seen in disorders such as Down syndrome and in many cancers.
“We also found that these chromosome errors can trigger inflammatory signals inside the cell.”
Aneuploidy means a cell has too many or too few chromosomes, which can disrupt normal growth and function.
Inflammatory signals are chemical messages that can make a cell behave as if it is responding to injury or infection.
“These cells behave almost as if they are under attack,” said Vagnarelli.
“The immune response switches on because the genome is unstable.
“That link between chromosome imbalance and inflammation could help explain patterns we see in several diseases.”
The researchers said the findings may help cancer scientists better understand how chromosome instability, loss of gene regulation and cells dividing before they are ready contribute to tumour growth.
They said understanding the normal machinery that prevents these errors may help researchers find ways to push cancer cells into making mistakes they cannot survive.
“We now have a clearer map of the machinery that resets the cell after division,” said Vagnarelli.
“That knowledge gives us a starting point for thinking about new therapeutic approaches.”
News
Abdominal obesity may lead to more severe menopause symptoms – study

Abdominal obesity may lead to worse menopause symptoms, including forgetfulness, irritability and night sweats, a new study suggests.
The findings point to a possible link between fat stored around the waist and more severe midlife symptoms.
Researchers said waist-to-height ratio could help identify women who may benefit from more targeted support.
Dr Monica Christmas is associate medical director for The Menopause Society.
Christmas said: “Unintended weight gain during the menopause transition, especially in the midsection, is one of the most commonly reported complaints, with the most significant gains experienced in the years leading up to the final menstrual period and a couple of years after.
“This not only affects self-image but also imposes negative health risks and, as the study highlights, is associated with higher prevalence and severity of menopause symptoms.”
The study used data from more than 1,100 women who took part in the Study of Women’s Health Across the Nation.
Abdominal obesity is a build-up of fat around the waist. It often includes visceral fat, which is deep, active fat surrounding internal organs.
This type of fat releases inflammatory proteins and toxic fatty acids that can contribute to insulin resistance, cardiovascular disease, high blood pressure and a higher risk of some cancers.
Insulin resistance means the body does not respond properly to insulin, the hormone that helps control blood sugar.
The Menopause Society said abdominal obesity is estimated to affect more than 60 per cent of menopausal women.
As oestrogen levels fall during menopause, women tend to store more fat around the waist rather than the hips, even if their overall weight does not change.
The researchers noted that obesity patterns and menopause symptom burden can vary by region, but research into the effect of abdominal obesity on these symptoms remains limited.
They also said earlier studies have mainly looked at single symptoms, rather than how symptoms connect with each other.
In this study, researchers used network analysis, a method that looks at how symptoms are linked, to compare symptom patterns in women with and without abdominal obesity.
They identified abdominal obesity using waist-to-height ratios, which compare waist size with height and can be used as a simple measure of health risk linked to body fat around the middle.
The researchers concluded that women with abdominal obesity had both a higher prevalence and greater severity of a range of symptoms, as well as a distinct symptom network structure.
In particular, women with abdominal obesity reported a higher prevalence and greater severity of dizziness, hot flashes and night sweats than women without abdominal obesity.
Sleep disturbances and palpitations were also reported more often in women with abdominal obesity. Palpitations are feelings of a fast, fluttering or pounding heartbeat.
The researchers said assessment of abdominal obesity using waist-to-height ratios may help stratify women who are likely to benefit from targeted, network-based interventions rather than isolated symptom management.
Christmas said: “Educating women early about healthy lifestyle interventions to prevent midlife weight gain is key to improving mental and physical well-being during a tumultuous time frame.”
News
Perimenopause may offer “window of opportunity” for heart disease prevention
Entrepreneur3 weeks agoFuture Fertility raises Series A financing to scale AI tools redefining fertility care worldwide
News2 weeks agoWomen’s digital health market set to reach US$5.28 billion in 2026 – report
Fertility4 weeks agoFuture Fertility partners with Japan’s leading IVF provider, Kato Ladies Clinic
Diagnosis3 weeks agoNew meta-analysis further supports low re-excisions and high placement accuracy with the Magseed marker
Mental health3 weeks agoLifting weights shows mental health and cognitive benefits in older women, study finds
Menopause3 weeks agoResistance training has preventative effects in menopause, study finds
Diagnosis3 weeks agoNIPT or NT scan? Why the 2026 evidence supports doing Both
News4 weeks agoRelaunched women’s health strategy aims to tackle ‘medical misogyny’














3 Comments